Navigation Links
Proteon Therapeutics Receives European Patent Covering New Method of Dilating Arteries and Veins
Date:3/13/2008

WALTHAM, Mass. and KANSAS CITY, Mo., March 13 /PRNewswire/ -- Proteon Therapeutics, Inc. (http://www.proteontherapeutics.com), announced today that a key patent has been issued by the European Patent Office. The patent (No. 1220830) covers the use of a class of proteins known as elastases for dilating arteries and veins in humans. This follows the issuance of related United States patents in June and December of 2006. Proteon Therapeutics owns all of these patents by assignment from Johns Hopkins University, where the underlying invention was made by F. Nicholas Franano, M.D.

"We are very pleased that the European Patent Office has joined with their U.S. counterparts in recognizing the fundamental breakthrough described in this patent," said Dr. Franano, Founder and Chief Scientific Officer of Proteon Therapeutics.

"The issuance of this patent further strengthens and broadens Proteon's elastase vasodilation franchise," said Timothy Noyes, President and Chief Executive Officer of Proteon Therapeutics. "With this patent in hand, Proteon Therapeutics can continue the global development of PRT-201, our lead drug candidate," added Noyes.

The law firm Dechert LLP, oversaw patent prosecution in Europe while the firm of Fried, Frank, Harris, Shriver & Jacobson LLP, served as lead U.S. patent counsel.

About Proteon Therapeutics

Proteon Therapeutics, Inc., is a privately held biopharmaceutical company developing novel, first-in-class pharmaceuticals to address the critical medical needs of patients with kidney and vascular diseases. The company is leveraging a unique understanding of tissue remodeling to develop a pipeline of proprietary pharmaceuticals. The company is headquartered in Waltham, MA, and has research facilities in Kansas City, MO. For additional information please visit http://www.proteontherapeutics.com.


'/>"/>
SOURCE Proteon Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Proteon Therapeutics Appoints Experienced Biopharmaceutical Executive, Gregory D. Phelps to its Board of Directors
2. Proteon Therapeutics to Present at Annual Meeting of American Society of Nephrology in San Francisco on November 2, 2007
3. Proteon Therapeutics Completes $12 Million Financing and Hires CFO
4. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
5. Oncolys BioPharma and Tacere Therapeutics Sign Strategic Alliance and License Agreement to Develop and Commercialize RNAi Hepatitis C Drug
6. Mercury Therapeutics, Inc: Lead Series of Indirect AMPK Activators Licensed to Makoto Life Sciences
7. Sirnaomics and GRL Establish Partnership for the Development of Two Multi-Targeted RNAi Therapeutics Products
8. Nile Therapeutics to Announce 2007 Fourth Quarter and Full Year Financial Results on Thursday, March 13, 2008
9. Halozyme Therapeutics Presents Favorable New Safety and Pharmacokinetic Data on rHuPH20 Enzyme Produced Via New Manufacturing Process at European Federation for Pharmaceutical Sciences
10. Alseres Pharmaceuticals Presents Inosine and Dopamine Transporter (DAT) Blocker Preclinical Data at the American Society for Experimental NeuroTherapeutics (ASENT) Conference
11. Elusys Therapeutics Appoints Robert Gundel as Vice President of Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/21/2017)... , ... February 21, 2017 ... ... Life -Sciences division, Treximo will pair its $200M operational capacity with its ... and project management in areas affecting quality and operational management. With ...
(Date:2/21/2017)... 21, 2017  Lexus, a returning partner of the Amgen ... and exclusive automobile partner of the men,s and women,s events for ... The 2017 Amgen Tour of California will ... of the best professional cycling teams in the world racing from ... four-day Amgen Breakaway from Heart Disease TM Women,s ...
(Date:2/21/2017)... -- Research and Markets has announced the addition of ... Industry Forecast to 2025" report to their offering. ... The Global Bioplastics & ... 12.8% over the next decade to reach approximately $8.9 billion by ... and forecasts for all the given segments on global as well ...
(Date:2/20/2017)... 2017 This report analyzes the worldwide markets for ... Xylanase, Amylase, Cellulase, and Others. The report provides separate comprehensive ... Japan , Europe , ... and Rest of World. Read the full ... are provided for the period 2015 through 2022. Also, a ...
Breaking Biology Technology:
(Date:2/8/2017)... -- Report Highlights The global biosurgery market ... in 2016 at a compound annual growth rate (CAGR) ... - An overview of the global market for biosurgery. ... 2015 and 2016, and projections of compound annual growth ... on the basis of product type, source, application, and ...
(Date:2/7/2017)... LONG BEACH, New York , February 7, 2017 ... formerly known as ID Global Solutions Corporation [OTC: IDGS], ... identification, identity management and electronic transaction processing services, is ... a reorganization of the Company. Effective January ... Chairman of the Board of Directors, CEO and President. ...
(Date:2/3/2017)... A new independent identity strategy consultancy firm announces its ... to fill a critical niche in technical and policy ... Mark Crego and Janice Kephart together ... that span federal governments, the 9/11 Commission, private industry, ... has a common theme born from a shared passion ...
Breaking Biology News(10 mins):